Tony W. Ho

2017

In 2017, Tony W. Ho earned a total compensation of $4.5M as EVP, Research and Development at CRISPR Therapeutics AG.

Compensation breakdown

Bonus$100,000
Non-Equity Incentive Plan$92,199
Option Awards$2,843,484
Salary$170,833
Stock Awards$1,267,500
Total$4,474,016

Ho received $2.8M in option awards, accounting for 64% of the total pay in 2017.

Ho also received $100K in bonus, $92.2K in non-equity incentive plan, $170.8K in salary and $1.3M in stock awards.

Rankings

In 2017, Tony W. Ho's compensation ranked 2,207th out of 14,666 executives tracked by ExecPay. In other words, Ho earned more than 85.0% of executives.

ClassificationRankingPercentile
All
2,207
out of 14,666
85th
Division
Manufacturing
759
out of 5,772
87th
Major group
Chemicals And Allied Products
206
out of 2,075
90th
Industry group
Drugs
155
out of 1,731
91st
Industry
Biological Products, Except Diagnostic Substances
32
out of 313
90th
Source: SEC filing on April 30, 2019.

Ho's colleagues

We found four more compensation records of executives who worked with Tony W. Ho at CRISPR Therapeutics AG in 2017.

2017

Samarth Kulkarni

CRISPR Therapeutics AG

Chief Executive Officer

2017

Rodger Novak

CRISPR Therapeutics AG

President

2017

Michael Tomsicek

CRISPR Therapeutics AG

Chief Financial Officer

2017

James Kasinger

CRISPR Therapeutics AG

General Counsel

News

In-depth

You may also like